Diabetic Lumbosacral Plexopathy Medication
- Author: Divakara Kedlaya, MBBS; Chief Editor: Robert H Meier III, MD more...
Medication Summary
Intravenous human immunoglobulin (IVIg) may hasten recovery in patients with diabetic lumbosacral plexopathy, although this treatment has not been proven in controlled studies and remains controversial.[24, 25, 26] A 2009 Cochrane review concluded that no evidence from randomized trials supports any recommendation on the use of immunotherapy treatment in diabetic lumbosacral plexopathy.[27]
Other immunosuppressive agents, such as cyclophosphamide and methylprednisolone, are also thought to improve recovery. Kilfoyle et al studied treatment with pulsed methylprednisolone at 500 mg for 2 days every 2 weeks instituted within 3 months of symptom onset and noted significant improvement in pain and weakness in the majority of patients.[28]
Blood Products
Class Summary
The administration of human immunoglobulins may improve the clinical and immunologic aspects of the disease. Blood products may decrease autoantibody production and increase solubilization and removal of immune complexes.
Immunoglobulins (Gamimune, Gammagard S/D, Sandimmune)
Immunoglobulin neutralizes circulating myelin antibodies through anti-idiotypic antibodies. In addition, it down-regulates proinflammatory cytokines, including interferon (IFN)-gamma; blocks Fc receptors on macrophages; suppresses inducer T-cells and B-cells and augments suppressor T-cells; blocks complement cascade; promotes remyelination; and may increase cerebrospinal fluid (CSF) levels of immunoglobulin (Ig) G (10%).
Immunosuppressive Agents
Class Summary
Immunosuppressive agents such as cyclophosphamide, methylprednisolone, and prednisone may improve recovery.
Cyclophosphamide
Cyclophosphamide is a cyclic polypeptide that suppresses some humoral activity. It is chemically related to nitrogen mustards and is activated in the liver to its active metabolite, 4-hydroxycyclophosphamide, which alkylates the target sites in susceptible cells in an all-or-none–type reaction. When used in autoimmune diseases, the mechanism of action is thought to involve immunosuppression due to destruction of immune cells via DNA cross-linking.
Azathioprine (Imuran)
Azathioprine is an imidazolyl derivative of 6-mercaptopurine. It antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. It works primarily on T cells and suppresses hypersensitivities of the cell-mediated type and causes variable alterations in antibody production.
Methylprednisolone (Medrol, Solu-Medrol)
Methylprednisolone is an immunosuppressant that decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Prednisolone
Prednisone is an immunosuppressant that can be used for the treatment of autoimmune disorders. It may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear activity. It stabilizes lysosomal membranes and suppresses lymphocyte and antibody production.
Tricyclic Antidepressants
Class Summary
These drugs have central and peripheral anticholinergic effects, as well as sedative effects, and block the active reuptake of norepinephrine and serotonin.
Amitriptyline
Amitriptyline is an oral analgesic for certain types of chronic pain. The usual adult dose ranges from 30-150 mg/d.
Nortriptyline (Pamelor)
Nortriptyline has demonstrated effectiveness in the treatment of chronic pain via inhibition of the reuptake of serotonin and/or norepinephrine by the presynaptic neuronal membrane. As a result, this drug increases the synaptic concentration of these neurotransmitters in the central nervous system (CNS). In addition, pharmacodynamic effects, such as the desensitization of adenyl cyclase and the down-regulation of beta-adrenergic receptors and serotonin receptors, appear to play a role in its mechanisms of action.
Doxepin (Silenor)
This agent inhibits histamine and acetylcholine activity and has proven useful in the treatment of various forms of depression associated with chronic and neuropathic pain.
Desipramine (Norpramin)
Desipramine may increase the synaptic concentration of norepinephrine in the CNS by inhibiting reuptake by presynaptic neuronal membrane. The drug may have effects in the desensitization of adenyl cyclase and in the downregulation of beta-adrenergic receptors and serotonin receptors.
Antiepileptic Drugs
Class Summary
These agents are used for neuropathic pain.
Gabapentin (Neurontin)
Gabapentin has anticonvulsant properties and antineuralgic effects; however, its exact mechanism of action is unknown. The drug is structurally related to gamma-aminobutyric acid (GABA) but does not interact with GABA receptors. Titration to effect can take place over several days (300 mg on day 1, 300 mg bid on day 2, and 300 mg tid on day 3).
Pregabalin (Lyrica)
Pregabalin is a structural derivative of GABA. The mechanism of action is unknown. It binds with high affinity to the alpha2-delta site (a calcium channel subunit). It is FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia and as adjunctive therapy in partial-onset seizures.
Bruns L. Uberneuritsche lahmungen beim diabetes mellitus. Berl Klin Wochenschr. 1890;27:509-15.
GARLAND H. Diabetic amyotrophy. Br Med J. Nov 26 1955;2(4951):1287-90. [Medline]. [Full Text].
Asbury AK. Proximal diabetic neuropathy. Ann Neurol. Sep 1977;2(3):179-80. [Medline].
Locke S, Lawrence DG, Legg MA. Diabetic amyotrophy. Am J Med. Jun 1963;34:775-85. [Medline].
Sander HW, Chokroverty S. Diabetic amyotrophy: current concepts. Semin Neurol. Jun 1996;16(2):173-8. [Medline].
Tracy JA, Dyck PJ. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. Feb 2008;19(1):1-26, v. [Medline]. [Full Text].
Raff MC, Asbury AK. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus. N Engl J Med. Jul 4 1968;279(1):17-21. [Medline].
Taylor BV, Dunne JW. Diabetic amyotrophy progressing to severe quadriparesis. Muscle Nerve. Oct 2004;30(4):505-9. [Medline].
Brown MJ, Asbury AK. Diabetic neuropathy. Ann Neurol. Jan 1984;15(1):2-12. [Medline].
Williams IR, Mayer RF. Subacute proximal diabetic neuropathy. Neurology. Feb 1976;26(2):108-16. [Medline].
Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. Dec 10 1999;53(9):2113-21. [Medline].
Harrison MJ, Casey EB. Diabetic amyotrophy. Br Med J. Jul 29 1972;3(5821):293. [Medline]. [Full Text].
Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc. Dec 1997;72(12):1123-32. [Medline].
Kawamura N, Dyck PJ, Schmeichel AM, Engelstad JK, Low PA, Dyck PJ. Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Acta Neuropathol. Feb 2008;115(2):231-9. [Medline].
Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. Apr 2002;25(4):477-91. [Medline].
Casey EB, Harrison MJ. Diabetic amyotrophy: a follow-up study. Br Med J. Mar 11 1972;1(5801):656-9. [Medline]. [Full Text].
Bastron JA, Thomas JE. Diabetic polyradiculopathy: clinical and electromyographic findings in 105 patients. Mayo Clin Proc. Dec 1981;56(12):725-32. [Medline].
Gulve EA. Exercise and glycemic control in diabetes: benefits, challenges, and adjustments to pharmacotherapy. Phys Ther. Nov 2008;88(11):1297-321. [Medline].
Russell JW, Berent-Spillson A, Vincent AM, Freimann CL, Sullivan KA, Feldman EL. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis. Jun 2008;30(3):420-9. [Medline]. [Full Text].
Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol. Nov 1991;48(11):1130-5. [Medline].
O'Neill BJ, Flanders AE, Escandon SL, Tahmoush AJ. Treatable lumbosacral polyradiculitis masquerading as diabetic amyotrophy. J Neurol Sci. Oct 22 1997;151(2):223-5. [Medline].
Tataroglu C, Bicerol B, Kiylioglu N, Ozkul A, Akyol A. Proximal femoral conductions in patients with lumbosacral radiculoplexus neuropathy. Clin Neurol Neurosurg. Oct 2007;109(8):654-60. [Medline].
Subramony SH, Wilbourn AJ. Diabetic proximal neuropathy. Clinical and electromyographic studies. J Neurol Sci. Feb 1982;53(2):293-304. [Medline].
Fernandes Filho JA, Nathan BM, Palmert MR, Katirji B. Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin. Muscle Nerve. Dec 2005;32(6):818-20. [Medline].
Kawagashira Y, Watanabe H, Oki Y, Iijima M, Koike H, Hattori N, et al. Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy. J Neurol Neurosurg Psychiatry. Aug 2007;78(8):899-901. [Medline]. [Full Text].
Wada Y, Yanagihara C, Nishimura Y, Oka N. A case of diabetic amyotrophy with severe atrophy and weakness of shoulder girdle muscles showing good response to intravenous immune globulin. Diabetes Res Clin Pract. Jan 2007;75(1):107-10. [Medline].
Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev. Jul 8 2009;CD006521. [Medline].
Kilfoyle D, Kelkar P, Parry GJ. Pulsed methylprednisolone is a safe and effective treatment for diabetic amyotrophy. J Clin Neuromuscul Dis. Jun 2003;4(4):168-70. [Medline].

